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The novel pyrrolopyrimidine-based antifolate MTA (LY231514,
N-[4[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrim-
indin-5-yl)-ethyl]-benzoyl]-L-glutamic acid) inhibits several
folate-dependent enzymes involved in de novo nucleotide bio-
synthesis, including thymidylate synthase (TS: E.C.2.1.1.45),
dihydrofolate reductase (DHFR: E.C.1.5.1.3) and glycinamide
ribonucleotide formyltransferase (GARFT: E.C.2.1.2.2) (Shih et
al, 1997). In addition, MTA is one of the best known substrates 
for mammalian folylpolyglutamate synthase (E.C.6.3.2.17) and
polyglutamation increases the intracellular retention of MTA and
MTA-induced inhibition of TS and GARFT. MTA is a potent
inhibitor of tumour cell growth in vitro, e.g. in CCRF-CEM
leukaemia cells (IC50 = 25 nM), GC3/C1 colon cells (IC50 = 34 nM)
and HCT-8 illoecaecal cells (IC50 = 220 nM) (Shih et al, 1997). The
multi-targeted nature of MTA has been confirmed in whole cell
investigations where end-product reversal studies have shown that
both thymidine and hypoxanthine are required to completely
reverse the antiproliferative effect of MTA (Shih et al, 1997). MTA
is currently undergoing phase II clinical trials in a range of tumour
types where promising activity has been observed (Calvert and
Walling, 1998).
Resistance to antifolates may be mediated by a number of
intrinsic or acquired mechanisms in cancer cells. One intrinsic
mechanism is circumvention of the block of de novo nucleotide
synthesis via the salvage of extracellular preformed nucleosides
and nucleobases (Weber, 1983). For example, extracellular thymi-
dine can be phosphorylated by thymidine kinase (E.C.2.7.1.21) to
dTMP hence by-passing inhibition of TS. Similarly, hypoxanthine
can be converted to IMP by hypoxanthine-guanine phosphoribosyl
transferase (E.C.2.4.2.8) thereby overcoming inhibition of de novo
purine synthesis. A number of factors may contribute to the overall
activity of the salvage pathway in tumours. In particular, the activ-
ities of salvage enzymes in cancer cells are higher than those of de
novo synthesis (Weber, 1983) and the activity of the salvage
pathway increases in parallel with malignancy (Kinsella and
Haran, 1991). Furthermore, the breakdown of dead and dying cells
in vivo may increase the concentration of salvageable nucleosides
and bases in the vicinity of the tumour. Thus nucleoside and
nucleobase salvage may compromise the in vivo activity of
antimetabolites, and inhibition of the salvage pathway should
therefore overcome this form of resistance.
The transport of salvageable nucleosides and nucleobases
across the cell membrane is the first step in the salvage pathway.
Nucleoside transport is mediated largely by equilibrative trans-
porters at physiological nucleoside concentrations (Plagemann and
Wohlhueter, 1984b). The cardiovascular agent dipyridamole (DP)
inhibits nucleoside transport in all human cell lines tested, and has
been used successfully to potentiate the activity of antifolates in
vitro. For example, DP potentiates CB3717 (an antifolate TS
inhibitor) by preventing the salvage of thymidine (Curtin and
Harris, 1988). Similarly, the cytotoxicity of methotrexate, which
inhibits both de novo thymidylate and purine biosynthesis, is
increased by DP in a variety of human and animal cells through
inhibition of thymidine and/or hypoxanthine uptake (Nelson and
Drake, 1984; Van Mouwerik et al, 1987; Hughes and Tattersall,
1989; Chan and Howell, 1990). DP has been shown to inhibit
hypoxanthine transport in some cell lines but not others
(Plagemann and Wohlhueter, 1984a), and has been used to
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antipurine antifolate-induced growth inhibition (Turner et al, 1997;
Marshman et al, 1998).
The aim of the investigation reported here was to determine the
effect of DP on reversal of MTA-induced growth inhibition by
thymidine and hypoxanthine in cells previously characterized for
their sensitivity to DP-mediated inhibition of hypoxanthine rescue
from antipurine antifolate toxicity (Marshman et al, 1998). Four
cell lines representing common human malignancies, two non-
small-cell lung carcinoma (NSCLC: A549 and COR L23) and two
breast carcinoma (MCF7 and T47D) were selected. In A549 and
MCF7 cells DP prevents hypoxanthine rescue from antipurine
antifolate-induced growth inhibition, whilst in COR L23 and
T47D cells DP has no effect on hypoxanthine rescue (Marshman et
al, 1998). On the basis of these data the cell lines were described as
having either dipyridamole  sensitive transport (ds, A549 and
MCF7) or dipyridamole-insensitive hypoxanthine transport (di,
COR L23 and T47D). The mechanism of rescue from MTA-
induced growth inhibition was examined by investigation of
thymidine and hypoxanthine uptake and its inhibition by DP in the
four cell lines.
MATERIALS AND METHODS
Materials
LY231514 (MTA, N-[4[2-(2-amino-3,4-dihydro-4-oxo-7H-
pyrrolo[2,3-d]pyrimindin-5-yl)-ethyl]-benzoyl]-L-glutamic acid)
was a gift from Eli Lilly and Co., USA. MTA was dissolved in
dH2O and stored at 4°C. Thymidine, hypoxanthine and dipyri-
damole (Sigma Chemical Company, Poole, UK) were dissolved in
dH2O, 0.1 M sodium hydroxide (NaOH) and 100% dimelthyl
sulphoxide (DMSO) respectively, and stored in the dark at 4°C for
a maximum of 4 weeks. All other reagents were obtained from
Sigma unless otherwise stated.
Cell culture
COR L23 (a kind gift from Dr P Twentyman, MRC Clinical
Oncology and Radiotherapeutics Unit, Cambridge, UK) and A549
(National Cancer Institute, National Institutes of Health, Bethesda,
MD, USA) non-small-cell lung carcinoma; MCF7 and T47D
breast adenocarcinoma (European Collection of Animal Cell
Cultures) were adapted to growth in RPMI-1640 medium supple-
mented with 1000 units ml–1 penicillin, 100 mg ml–1 streptomycin
(Gibco, Paisley, UK) and 10% (v/v) fetal calf serum that had been
dialysed (four changes of 9 volumes phosphate-buffered saline
(PBS) + 1 g L–1 activated charcoal) to remove salvageable nucleo-
sides and bases. All cells were maintained as exponentially
growing cultures. Cells were tested every month for mycloplasma
contamination using a Hoechst 33258 DNA fluorescence-based
technique (Chen, 1977) and found to be negative.
Growth inhibition assays
The optimum cell seeding density was determined to be 1 ´ 103
cells well–1 for A549 and COR L23 cells, 2 ´ 103 for T47D cells
and 3 ´ 103 for MCF7 cells. Cells were incubated in 96-well plates
(Nunc) and grown at 37°C in a humidified atmosphere at 5%
carbon dioxide. Following incubation the plates were washed with
PBS, fixed with methanol:acetic acid (3:1 v/v), washed, air-dried
and stained with sulphorhodamine B (SRB) as described previ-
ously (Skehan et al, 1990). The optical density relative to an air
blank was measured on a Dynatech MR7000 96-well microtitre
plate reader (Dynatech) using a 570 nm filter.
Cells in logarithmic phase growth were harvested with trypsin,
seeded at 1–3 ´ 103 in 100-ml in 96-well plates and allowed to
attach to the plate overnight. The medium was replaced with that
containing semi-logarithmic dilutions of MTA for A549, CORL 23
and MCF7 cells and logarithmic dilutions of MTA for T47D cells
for a period equivalent to three population doubling times (72, 96,
144 and 96 h for A549, COR L23, MCF7 and T47D cells respec-
tively). The IC50 values (concentration causing 50% inhibition of
growth) were determined by non-linear regression fitting of a
sigmoid curve to the data using GraphPad PRISM™ (San Diego,
CA, USA) software. End product reversal experiments and inves-
tigations of the effect of DP were conducted using a fixed concen-
tration of MTA at the IC50 or 10 ´ IC50 determined as above for
each cell line. Thus A549, COR L23, MCF7 and T47D cells were
exposed to 700 nM or 7000 nM, 20 nM or 200 nM, 50 nM or 500 nM
and 50 nM or 500 nM MTA respectively, ± 1–10 mM thymidine,
1–30 mM hypoxanthine and/or 1 mM DP in 1% (v/v) DMSO for
three cell doublings followed by SRB assay as described above.
Thymidine transport assays
A modified rapid mixing technique (Wolhueter et al, 1978),
combined with the inhibitor-stop method of Paterson et al (1981),
was used as described below. Uptake was measured over a 12-s
period to calculate initial rates of transport as opposed to subse-
quent metabolism. For each thymidine concentration, six replicate
0.4 ml microtest tubes (BDH) were prepared by adding 50 ml 3 M
potassium hydroxide (KOH) followed by a layer of Dow Corning
silicone oil (specific gravity of 1.028). Cells in logarithmic phase
growth were harvested with PBS containing 400 mg L–1 EDTA and
centrifuged at 1850 g at 4°C for 5 min. The cell pellet was re-
suspended in transport buffer (130 mM sodium chloride (NaCl), 
5m M potassium chloride (KCl), 1 mM magnesium chloride
(MgCl2) 5 mM NaH2PO4, 10 mM glucose, 25 mM HEPES at pH
7.1) and centrifuged again before re-suspension in transport buffer
at 4 ´ 107 cells ml–1. Cell suspensions (333 ml) were incubated with
50  ml DMSO ± DP (20 ´ final concentration) 283 ml transport
buffer and incubated at 21°C for 6 min. One to 2 ´ 106 cells were
then layered over the oil layer in six separate microfuge tubes. Cell
number and viability were confirmed by counting and trypan blue
exclusion. Transport was initiated by addition of radiolabel
mixture (containing 3H-thymidine (final specific activity 6.2 Gbq
mmol–1), 14C-sucrose (final specific activity 7.4 Gbq mmol–1) and
transport buffer resulting in a final concentration of 100 mM thymi-
dine) at 1-s time intervals. After exposure to thymidine for 2, 4, 6,
8, 10 and 12 s transport was terminated by the addition of 400 mM
DP. The tubes were immediately transferred to an Eppendorf
(5415 C) microcentrifuge (Eppendorf, Hamburg, Germany) and
pulse centrifuged at 6700 g to pellet the cells into the KOH layer.
The tubes were left for 1 h to allow the cells to dissolve in the
KOH layer and the tubes were then cut through the oil layer and
the bottom section containing the KOH transferred to a scintilla-
tion vial. The KOH was neutralized by the addition of 1 ml of 0.25
M acetic acid and 10 ml Optiphase Hisafe (Wallac, Milton Keynes,
UK) scintillation fluid was added. The samples were then counted
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Milton Keynes, UK). Since 14C-sucrose does not enter the cells,
the ratio of 14C:3H was used to calculate the amount of contami-
nating 3H-thymidine in the extracellular space in each sample. The
contaminating  3H-thymidine was subtracted from the total 3H-
thymidine count in order to calculate the amount of thymidine
transport at each time point.
Hypoxanthine transport assay
Cells in logarithmic phase growth were harvested with PBS
containing 400 mg L–1 EDTA and centrifuged at 1850 g at 4°C for
5 min. The cell pellet was re-suspended in hypoxanthine transport
buffer (140 mM NaCl, 10 mM HEPES at pH 7.4) and centrifuged
again before resuspending in transport buffer. Cells were incu-
bated with 5% (v/v) DMSO (control) or dipyridamole dissolved in
DMSO for 5 min at 21°C. A 100 ml aliquot of this suspension was
pipetted into 0.4-ml microfuge tubes containing a layer of 200 ml
Dow Corning silicone oil (final specific gravity 1.028) over 50 ml
3 M KOH. Transport was initiated by the addition of 50 ml of
radiolabel containing [8-3H]-hypoxanthine (final specific activity
0.13 Gbq mmol–1) and [U-14C]-sucrose (final specific activity 
7.4 Gbq mmol–1) giving a final concentration of 30 mM HPX in
transport buffer. Transport was measured over ten seconds and was
stopped by centrifugation at 6700 g for 2 min of the cells through
the oil layer into the KOH layer. Tubes were then processed as
described for thymidine transport measurements.
RESULTS
The cell doubling time and optimum seeding density to give expo-
nential growth during the exposure period was determined for
each cell line by daily SRB assays of replicate 96-well plates
seeded with varying initial cell densities. The doubling times esti-
mated in this manner are given in Table 1. Cell growth inhibition
was determined following continuous exposure to increasing
concentrations of MTA for at least three population doublings. The
IC50 concentrations, defined as the concentration of drug required
to inhibit cell growth by 50%, are given in Table 1. A broad range
of sensitivities to MTA was observed with A549 cells (IC50 = 640
nM) being the least sensitive and COR L23 cells (IC50 = 28 nM)
being the most sensitive (Table 1).
End product reversal studies in CCRF-CEM cells have shown
that thymidine can prevent MTA-induced growth inhibition at
concentrations at or below the MTA IC50, but that thymidine and
hypoxanthine are required for complete rescue at concentrations
above the MTA IC50 (Shih et al, 1997). To investigate if a similar
pattern of end product reversal was observed in breast and lung
cancer cell lines, each cell line was exposed to the IC50 and 10 ´
IC50 concentration of MTA in the presence of increasing concen-
trations of thymidine (1 mM, 5 mM and 10 mM) (Figure 1). All cell
lines displayed complete reversal of MTA-induced growth inhibi-
tion at the IC50 concentration in the presence of thymidine. In
A549 and COR L23 cells, 1 mM thymidine was sufficient to afford
complete reversal of MTA-induced growth inhibition at the IC50
concentration; however, in MCF7 and T47D cells 5 mM thymidine
was required. In all cells, only partial reversal of MTA-induced
growth inhibition was observed following treatment with MTA at
a concentration of 10 ´ the IC50, even when the concentration of
thymidine was raised to 10 mM. Thymidine alone (1–10 mM) did
not affect the growth of any of the cell lines (data not shown).
Hypoxanthine alone (1–30 mM) conferred no reversal of growth
inhibition following exposure to 10 ´ IC50 concentrations of MTA
in any of the four cell lines tested (Figure 2), and 1 mM hypoxan-
thine did not enhance the partial rescue afforded by thymidine in
any cell line. However, the combination of 30 mM hypoxanthine 
+ 1 mM thymidine gave complete reversal of the growth inhibitory
effects of MTA at a concentration of 10 ´ the IC50.
In cells exposed to 10 ´ IC50 concentrations of MTA, DP (1 mM)
inhibited the partial rescue afforded by thymidine in all four cell
lines (Figure 3). DP has previously been shown to inhibit hypo-
xanthine rescue from antipurine antifolates in A549 and MCF7
cells but not in COR L23 and T47D cells (Marshman et al, 1998).
However, in the study demonstrated here, DP completely inhibited
the reversal of MTA-induced growth inhibition by the combina-
tion of thymidine and hypoxanthine in all cells tested.
Interestingly, A549 cell growth was reduced to 11 ± 4% of control
by the combination of MTA (at 10 ´ IC50) + 1 mM DP and, in the
additional presence of thymidine and hypoxanthine reduced to 10
± 3% of control, this was more growth inhibitory than the cell
growth produced by MTA (at 10 ´ IC50) alone which was reduced
to 19 ± 2% of control.
To confirm that the inhibition of rescue produced by DP was
due to the inhibition of thymidine and hypoxanthine uptake, trans-
port assays were performed using 100 mM 3H-thymidine and 30 mM
3H-hypoxanthine in the presence or absence of 1 mM and 10 mM
DP. One mM DP was sufficient to inhibit thymidine transport by 
> 89% in all four cell lines (Table 2). Hypoxanthine transport was
significantly reduced in A549 cells by 45% (P < 0.05) and by 60%
(P < 0.05) in MCF7 cells at 1 mM DP and was inhibited further by
69% and 89% in A549 and MCF7 cells, respectively, at 10 mM DP.
In contrast, DP (10 mM) did not cause a significant inhibition of
hypoxanthine transport in COR L23 cells (25%, P > 0.1) cells or in
T47D cells (30%, P > 0.1).
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Table 1 MTA-induced inhibition of cell growth
Cell line Tissue type Doubling time Exposure period MTA IC50 concentration
(h) (h) (nM)
A549 Lung 20 72 640±25
COR L23 Lung 31 96 28±14
MCF-7 Breast 45 144 52±5
T47D Breast 32 96 46±1
Cell doubling times were determined using log-linear plots of daily SRB assay data using GraphPad
PRISM™. Growth inhibition was determined following exposure to MTA for the time periods given. The IC50
is the concentration of MTA required to inhibit the growth of the cell population by 50%. Data are the 
mean ± standard deviation from three independent experiments.Potentiation of MTA (LY231514) by dipyridamole 927
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Figure 1 Thymidine rescue from MTA-induced growth inhibition in (A) A549, (B) COR L23, (C) MCF7 and (D) T47D cells. Cell growth was determined by the
SRB assay following exposure to an IC50 MTA concentration (solid line, closed symbols), or 10 ´ the IC50 concentration (broken line, open symbols), in the
presence of increasing thymidine concentrations for three cell doublings. Data are the mean ± standard deviation from three independent experiments
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Figure 2 Thymidine and hypoxanthine rescue from MTA growth inhibition in (A) A549, (B) COR L23, (C) MCF7 and (D) T47D cells. Cell growth was
determined by the SRB assay following exposure to 10 ´ the MTA IC50 concentration, in the presence or absence of 1 mM thymidine and 1 or 30 mM
hypoxanthine for three cell doublings. Data are the mean ± standard deviation from three independent experimentsDISCUSSION
The studies described in this paper were performed to determine
the sensitivity of four solid tumour cell lines to MTA, end-product
reversal of growth inhibition by thymidine and hypoxanthine, and
inhibition of end-product reversal by DP. To allow direct compar-
ison of the cell lines, the exposure period for each individual cell
line was adjusted so that untreated cells underwent at least three
cell doublings. The four cell lines used in this study varied ³ 20-
fold in their sensitivity to MTA, A549 cells (IC50 = 640 nM) being
the least sensitive followed by MCF7 and T47D cells and COR
L23 (IC50 = 28 nM) the most sensitive. The IC50 data calculated for
A549, COR L23 and MCF7 cells, based on semi-logarithmic dilu-
tions of MTA accurately predicted the concentration of MTA to
inhibit cell growth inhibition by 50% (Figure 1), whereas that
calculated from exposure to logarithmic dilutions of MTA in
T47D cells apparently underestimated sensitivity and the calcu-
lated IC50 inhibited growth by approximately 85% (Figure 1).
Previous studies with lometrexol and LY309887 (two GARFT
inhibitors) indicate a very similar rank order of sensitivity, i.e.
T47D (most sensitive) > CORL23 > MCF7 > A549 cells (least
sensitive) (Marshman et al, 1998). Thus, the inter-cell variation in
sensitivity to MTA, lometrexol and LY309887 could be due to
common factors such as antifolate transport and intracellular
polyglutamation.
In order to compare end product reversal data, all cell lines were
exposed to equiactive concentrations of MTA, i.e. at the IC50 or 
10 ´ the IC50 concentration. End product reversal experiments
928 PG Smith et al
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Figure 3 Prevention of thymidine and hypoxanthine rescue from MTA-induced growth inhibition by dipyridamole in (A) A549, (B) COR L23, (C) MCF7 and 
(D) T47D cells. Cell growth was determined by the SRB assay following exposure to 10 ´ the MTA IC50 concentration in the presence or absence of 1 mM
thymidine, 30 mM hypoxanthine and 1 mM dipyridamole for three cell doublings. Data are the mean ± standard deviation from three independent experiments
Table 2 Inhibition of thymidine (100 mM) and hypoxanthine (30 mM) transport by dipyridamole
Cell line Thymidine transport: % inhibition Hypoxanthine transport: %inhibition
+ 1 mM DP + 10 mM DP + 1 mM DP + 10 mM DP
A549 97±39 8 ±3.3 45±26 9 ±12
COR L23 94±29 4 ±51 2 ±62 5 ±18
MCF-7 89±19 5 ±46 0 ±48 9 ±12
T47D 94±49 7 ±26 ±18 30±19
Thymidine (100 mM) and hypoxanthine (30 mM) transport was measured over 10 s following the incubation of
cells ± DP prior to initiation of transport. Data are mean ± standard deviation from three independent
experiments.revealed that 1 mM thymidine alone completely reversed growth
inhibition produced by IC50 concentrations of MTA in all four cell
lines. At 10 ´ the IC50 concentration cell growth was still inhibited
by approximately 50% even when the concentration of thymidine
was increased to 10 mM. However, complete rescue from 10 ´ IC50
concentrations of MTA in all four cell lines was achieved by the
combination of 1 mM thymidine plus 30 mM hypoxanthine. This
result indicates that all four cell lines had functional thymidine 
and hypoxanthine uptake and salvage pathways, and that both
nucleotide precursors are required to overcome the inhibition of de
novo nucleotide biosynthesis by MTA. Similar observations have
been reported in CCRF-CEM leukaemia, GC3/C1 colon carci-
noma and HCT-8 iloecaecal carcinoma cells (Shih et al, 1997).
Thus, at IC50 concentrations of MTA TS appears to be the principal
locus of action whilst at higher MTA concentrations a pre-formed
purine is required for complete reversal of growth inhibition
suggesting that inhibition of de novo purine synthesis also occurs.
This is most likely due to the relative potencies of MTA for folate-
requiring enzymes; the inhibitory potency of the pentaglutamate of
MTA is 50´ and 5´ greater for TS (Ki = 1.3 nM) than GARFT 
(Ki = 65 nM) and DHFR (Ki = 7.2 nM) respectively (Shih et al,
1997). Although not tested in the cell lines used here raltitrexed,
which has a 90 000´ and 66´ greater potency for TS than GARFT
and DHFR (Ward et al, 1992; Shih et al, 1997), requires only
thymidine for complete reversal of growth inhibition even at high
concentrations in various cell types (Jackman et al, 1991; Shih et
al, 1997).
The concentrations of thymidine and hypoxanthine used in this
study are slightly higher than those found in normal human
plasma. In cancer patients thymidine levels have been shown to
range between 0.07 and 0.8 mM (Howell et al, 1981; Taylor et al,
1984; Traut, 1994) and hypoxanthine levels have been recorded at
0.9 mM (Wung and Howell, 1984). However, significant variations
in purines and pyrimidines are found in different tissues (Traut,
1994) and, in contrast to the in vitro setting, there is a continual
supply of these salvageable components. Furthermore, hypoxan-
thine and thymidine concentrations in tumours may be greater than
in plasma due to release from dead and dying cells. Thus, tumour
cells are likely to be continuously exposed to salvageable nucleo-
sides and bases, and nucleoside and base salvage therefore has the
potential to reduce the efficacy of MTA in cancer patients.
Dipyridamole has previously been shown to prevent thymidine
and/or hypoxanthine reversal of methotrexate cytotoxicity in a
variety of cell types (Nelson and Drake, 1984; Van Mouwerik et al,
1987; Hughes and Tattersall, 1989; Chan and Howell, 1990). In
order to determine if inhibition of hypoxanthine uptake by DP has
any bearing on the prevention of reversal in MTA-treated cells, the
effect of DP on thymidine and hypoxanthine rescue was tested in the
four cell lines which have previously been characterized as having
either DP sensitive (A549 and MCF7) or DP insensitive (COR L23
and T47D) hypoxanthine rescue from antipurine antifolate-induced
growth inhibition (Marshman et al, 1998). DP not only inhibited the
partial rescue of MTA-induced growth inhibition by thymidine
alone, but also the complete rescue produced by the combination of
thymidine and hypoxanthine in all cell lines tested. As hypoxanthine
alone did not reverse MTA-induced growth inhibition the inhibition
of thymidine salvage alone is sufficient to explain the prevention of
thymidine and hypoxanthine rescue by DP.
The combination of MTA + DP, in the presence or absence of
thymidine and hypoxanthine, was significantly more growth
inhibitory than MTA alone in A549 cells. This enhancement of
MTA activity is probably due to DP-mediated inhibition of
deoxyuridine efflux as previously observed in A549 cells exposed
to the antifolate TS inhibitor CB3717 (Curtin and Harris, 1988).
Subsequently, it was shown that in CB3717-treated A549 cells
inhibition of deoxyuridine efflux by DP lead to an increased intra-
cellular dUTP pool, DNA strand break levels and cell death
(Curtin et al, 1991).
To investigate the mechanism underlying the inhibition of
thymidine and hypoxanthine rescue by DP, the effect of DP on the
uptake of thymidine and hypoxanthine was determined in all four
cell lines. Hypoxanthine transport was not significantly inhibited
by 1 mM DP in T47D or COR L23 cells; however, transport was
inhibited by 45% and 60% in A549 and MCF7 cells, respectively,
consistent with the reported sensitivity (A549 and MCF7) and
insensitivity (COR L23 and T47D) to DP of hypoxanthine-
mediated reversal from LY309887 growth inhibition (Marshman
et al, 1998).
The data presented here indicate that DP can inhibit the reversal
of MTA-induced growth inhibition by thymidine and hypo-
xanthine in both non-small-cell lung cancer and breast cancer cell
lines, irrespective of the dipyridamole-sensitivity of their hypo-
xanthine transport. Inhibition of nucleoside and base transport by
DP may therefore represent a novel means of enhancing the anti-
tumour activity of MTA. However, attempts to use DP clinically to
potentiate antimetabolite activity have so far proved unsuccessful
(Wadler et al, 1987; Wilson et al, 1989). A significant problem
with the clinical use of DP is the avid binding of DP to the serum
protein a1 acid glycoprotein (Mahoney et al, 1982). There is a
wide variation in a1 acid glycoprotein in humans, with normal
levels between 0.5 and 1 mg ml–1 and levels in cancer patients
generally being elevated to 1–3 mg ml–1 (Kremer et al, 1988). In
vitro, potentiation of the growth inhibitory activity of CB3717 by
DP was reduced in a concentration-dependent manner by a1 acid
glycoprotein (Curtin et al, 1989), and the high a1 acid glycoprotein
levels in cancer patients may therefore explain the disappointing
clinical results obtained so far with DP. DP analogues that lack a1
acid glycoprotein binding are currently being developed and these
compounds may allow the clinical evaluation of MTA given in
combination with a nucleoside and base transport inhibitor.
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